Is there a risk of esketamine misuse in clinical practice?
In 2019, intranasal esketamine gained approval as a promising therapy for those individuals grappling with treatment-resistant depression. Both clinical trials and real-world studies have underscored its efficacy in alleviating and remitting depressive symptoms, with sustained benefits observed for...
Saved in:
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-01-01
|
Series: | Therapeutic Advances in Drug Safety |
Online Access: | https://doi.org/10.1177/20420986241310685 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|